Human LILRB3/CD85a/ILT5 PE-conjugated Antibody Summary
Accession # AAB68668
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of LILRB3/CD85a/ILT5 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) gated on monocytes were stained with Mouse Anti-Human CD14 APC-conjugated Monoclonal Antibody (Catalog # FAB3832A) and either (A) Mouse Anti-Human LILRB3/CD85a/ILT5 PE-conjugated Monoclonal Antibody (Catalog # FAB1806P) or (B) Mouse IgG2APhycoerythrin Isotype Control (Catalog # IC003P). View our protocol for Staining Membrane-associated Proteins.
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Immunoglobulin-like transcript 5 (ILT5), also known as leukocyte immunoglobulin-like receptor subfamily B (LILRB3), leukocyte immunoglobulin-like receptor 3 (LIR3) and CD85a, is an Ig-like receptor family member that is involved in immune regulation. ILT5 belongs to subfamily B whose members have cytoplasmic tails that contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events via phosphatase SHP-1. The counterpart to subfamily B is subfamily A, whose members qualify as activating receptors that lack ITIMs, but signal through association with FcR gamma. ILTs share structural homology and chromosomal localization with the KIR family of receptors (1, 2). Mature ILT5 is a highly polymorphic 85‑95 kDa glycoprotein that consists of a 420 amino acid (aa) extracellular domain (ECD) with four Ig-like domains, a 21 aa transmembrane segment, and a 167 aa cytoplasmic domain with three ITIMs (3, 4). Alternate splicing generates an isoform with a 17 aa insertion in the juxtamembrane ECD. In mouse and rat, the LILRB3 gene encodes the PIR-B protein which has six Ig-like domains. Rodent PIR-B and human ILT5 share 55% aa sequence identity within common regions of their ECDs. Both PIR-B and ILT5 are receptors for S. aureus, and activation of these receptors by bacteria influences the innate immune response triggered by TLRs (4). ILT5 is expressed on the surface of peripheral monocytes, neutrophils, eosinophils, basophils, and mast cell progenitors but not on mature mast cells (5‑7). On basophils, cross-linking of ILT5 to the activating receptors ILT1/LIR7 or Fc epsilon RI inhibits the release of histamine, leukotriene C4, and IL-4 (6). On osteoclast precursors, ILT5 ligation inhibits RANKL or M-CSF induced differentiation (8). ILT5 is down‑regulated on macrophages in rheumatoid arthritis synovial tissue following successful treatment with DMARD anti-rheumatic drugs (9).
Brown, D. et al. (2004) Tissue Antigens 64:215.
Borges, L. and D. Cosman (2000) Cytokine Growth Factor Rev. 11:209.
SwissProt Accession # O75022.
Nakayama, M. et al. (2007) J. Immunol. 178:4250.
Tedla, N. et al. (2003) Proc. Natl. Acad. Sci. 100:1174.
Sloane, D.E. et al. (2004) Blood 104:2832.
Tedla, N. et al. (2008) J. Leukoc. Biol. 83:334.
Mori, Y. et al. (2008) J. Immunol. 181:4742.
Huynh, O.A. et al. (2007) Rheumatology 46:742.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human LILRB3/CD85a/ILT5 PE-conjugated Antibody
Average Rating: 5 (Based on 2 Reviews)
Have you used Human LILRB3/CD85a/ILT5 PE-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
the antibody was used to analyzed the expression level of ILT5 in BDCA1,BDCA3 and pDCs.